Factor XII: form determines function

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 8, 2016, Pages 1498-1506

  de Maat, S ^a   Maas, C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

blood coagulation; bradykinin; factor XII; plasmin; prekallikrein

Indexed keywords

BLOOD CLOTTING FACTOR 12; BRADYKININ; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; KAOLIN; KININOGEN; PLASMA PROTEIN; PLASMIN; POLYPHOSPHATE; PREKALLIKREIN;

BIOCHEMISTRY; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; HEMOSTASIS; HUMAN; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; THROMBOSIS;

EID: 84983268664     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13383     Document Type: Review

References (75)

1. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case–control study. Lancet Neurol 2009; 8: 998–1005.
2. Larsson M, Rayzman V, Nolte MW, Nickel KF, Bjorkqvist J, Jamsa A, Hardy MP, Fries M, Schmidbauer S, Hedenqvist P, Broome M, Pragst I, Dickneite G, Wilson MJ, Nash AD, Panousis C, Renne T. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6: 222ra17.
3. Basir A, de Groot P, Grundeman PF, Tersteeg C, Maas C, Barendrecht A, van Herwaarden J, Kluin J, Moll F, Pasterkamp G, Roest M. In vitro hemocompatibility testing of Dyneema purity fibers in blood contact. Innovations (Phila) 2015; 10: 195–201.
4. Hong J, Andersson J, Ekdahl KN, Elgue G, Axen N, Larsson R, Nilsson B. Titanium is a highly thrombogenic biomaterial: possible implications for osteogenesis. Thromb Haemost 1999; 82: 58–64.
5. Long YM, Zhao XC, Clermont AC, Zhou QF, Liu Q, Feener EP, Yan B, Jiang GB. Negatively charged silver nanoparticles cause retinal vascular permeability by activating plasma contact system and disrupting adherens junction. Nanotoxicology. 2016; 10: 501–11.
6. Nabeshi H, Yoshikawa T, Matsuyama K, Nakazato Y, Arimori A, Isobe M, Tochigi S, Kondoh S, Hirai T, Akase T, Yamashita T, Yamashita K, Yoshida T, Nagano K, Abe Y, Yoshioka Y, Kamada H, Imazawa T, Itoh N, Kondoh M. Amorphous nanosilicas induce consumptive coagulopathy after systemic exposure. Nanotechnology 2012; 23: 045101.
7. Simberg D, Zhang WM, Merkulov S, McCrae K, Park JH, Sailor MJ, Ruoslahti E. Contact activation of kallikrein–kinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo. J Control Release 2009; 140: 301–5.
8. de Maat S, de Groot PG, Maas C. Contact system activation on endothelial cells. Semin Thromb Hemost 2014; 40: 887–94.
9. de Maat S, Tersteeg C, Herczenik E, Maas C. Tracking down contact activation – from coagulation in vitro to inflammation in vivo. Int J Lab Hematol 2014; 36: 374–81.
10. Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296–303.
11. Long AT, Kenne E, Jung R, Fuchs TA, Renne T. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost 2016; 14: 427–37.
12. Schmaier AH. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. J Thromb Haemost 2016; 14: 28–39.
13. Ten Cate H. Challenging the anticoagulant paradigm? J Thromb Haemost 2016; 14: 134–36.
14. LaRusch GA, Mahdi F, Shariat-Madar Z, Adams G, Sitrin RG, Zhang WM, McCrae KR, Schmaier AH. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 2010; 115: 5111–20.
15. Vroman L. Finding seconds count after contact with blood (and that is all I did). Colloids Surf B Biointerfaces 2008; 62: 1–4.
16. Vroman L, Lukosevicius A. Ellipsometer recordings of changes in optical thickness of adsorbed films associated with surface activation of blood clotting. Nature 1964; 204: 701–3.
17. Tans G, Rosing J, Griffin JH. Sulfatide-dependent autoactivation of human blood coagulation factor XII (Hageman factor). J Biol Chem 1983; 258: 8215–22.
18. Bjorkqvist J, Lecher B, Maas C, Renne T. Zinc-dependent contact system activation induces vascular leakage and hypotension in rodents. Biol Chem 2013; 394: 1195–204.
19. de Maat S, van Dooremalen S, de Groot PG, Maas C. A nanobody-based method for tracking factor XII activation in plasma. Thromb Haemost 2013; 110: 458–68.
20. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457–67.
21. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Muller-Esterl W, Wuillemin WA, Nilsson G, Renne T. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258–68.
22. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388–93.
23. Bock PE, Srinivasan KR, Shore JD. Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid–metal ion complexes are the activating species. Biochemistry 1981; 20: 7258–66.
24. Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Rienstra CM, Morrissey JH. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353–59.
25. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143–56.
26. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renne T, Gruber A, Gailani D. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981–9.
27. Decrem Y, Rath G, Blasioli V, Cauchie P, Robert S, Beaufays J, Frere JM, Feron O, Dogne JM, Dessy C, Vanhamme L, Godfroid E. Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med 2009; 206: 2381–95.
28. Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, Gailani D, Monia BP, MacLeod AR. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302–11.
29. Donovan AJ, Kalkowski J, Smith SA, Morrissey JH, Liu Y. Size-controlled synthesis of granular polyphosphate nanoparticles at physiologic salt concentrations for blood clotting. Biomacromolecules 2014; 15: 3976–84.
30. Fitch-Tewfik JL, Flaumenhaft R. Platelet granule exocytosis: a comparison with chromaffin cells. Front Endocrinol (Lausanne) 2013; 4: 1–11.
31. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602–13.
32. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15: 665–73.
33. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271–81.
34. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010; 125: 210–15.
35. Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 1996; 238: 240–9.
36. Citarella F, Wuillemin WA, Lubbers YT, Hack CE. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 1997; 99: 197–205.
37. Maas C. The protease storm of angioedema. J Angioedema 2013; 1: 18–27.
38. Schmaier AH. The elusive physiologic role of factor XII. J Clin Invest 2008; 118: 3006–9.
39. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37: 375–81.
40. Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 1976; 73: 2554–8.
41. Ravon DM, Citarella F, Lubbers YT, Pascucci B, Hack CE. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood 1995; 86: 4134–43.
42. Asmis LM, Sulzer I, Furlan M, Lammle B. Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb Res 2002; 105: 463–70.
43. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003–10.
44. Krishnaswamy S. The transition of prothrombin to thrombin. J Thromb Haemost 2013; 11(Suppl. 1): 265–76.
45. Hovinga JK, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lammle B. Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353–>Pro leading to loss of a kallikrein cleavage site. Blood 1994; 84: 1173–81.
46. Hedstrom L. Serine protease mechanism and specificity. Chem Rev 2002; 102: 4501–24.
47. Bode W, Schwager P. The refined crystal structure of bovine beta-trypsin at 1.8 A resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0. J Mol Biol 1975; 98: 693–717.
48. Ratnoff OD, Saito H. Amidolytic properties of single-chain activated Hageman factor. Proc Natl Acad Sci USA 1979; 76: 1461–63.
49. Engel R, Brain CM, Paget J, Lionikiene AS, Mutch NJ. Single-chain factor XII exhibits activity when complexed to polyphosphate. J Thromb Haemost 2014; 12: 1513–22.
50. Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 1978; 147: 719–29.
51. Pathak M, Wilmann P, Awford J, Li C, Hamad BK, Fischer PM, Dreveny I, Dekker LV, Emsley J. Coagulation factor XII protease domain crystal structure. J Thromb Haemost 2015; 13: 580–91.
52. Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy 2015; 70: 506–13.
53. Sala-Cunill A, Bjorkqvist J, Senter R, Guilarte M, Cardona V, Labrador M, Nickel KF, Butler L, Luengo O, Kumar P, Labberton L, Long A, Di Gennaro A, Kenne E, Jamsa A, Krieger T, Schluter H, Fuchs T, Flohr S, Hassiepen U. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 2015; 135: 1031–43.
54. Cichon S, Martin L, Hennies HC, Müller F, van Driessche K, Karpushova A, Stevens W, Colombo R, Renné T, Drouet C, Bork K, Nöthen MM. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098–104.
55. Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141: 31–35.
56. Bjorkqvist J, de Maat S, Lewandrowski U, Di Gennaro A, Oschatz C, Schonig K, Nothen MM, Drouet C, Braley H, Nolte MW, Sickmann A, Panousis C, Maas C, Renne T. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125: 3132–46.
57. Bork K, Wulff K, Hardt J, Witzke G, Lohse P. Characterization of a partial exon 9/intron 9 deletion in the coagulation factor XII gene (F12) detected in two Turkish families with hereditary angioedema and normal C1 inhibitor. Haemophilia 2014; 20: e372–5.
58. de Maat S, Bjorkqvist J, Suffritti C, Wiesenekker CP, Nagtegaal W, Koekman A, van Dooremalen S, Pasterkamp G, de Groot PG, Cicardi M, Renne T, Maas C. Plasmin is a natural trigger for bradykinin production in hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 2016. Apr 6. pii: S0091-6749(16)30006-9. doi: 10.1016/j.jaci.2016.02.021.
59. Blohme G. Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Med Scand 1972; 192: 293–8.
60. Munch EP, Weeke B. Non-hereditary angioedema treated with tranexamic acid. A 6-month placebo controlled trial with follow-up 4 years later. Allergy 1985; 40: 92–7.
61. Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, Martin L, Gompel A, Bouillet L. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol 2014; 178: 112–7.
62. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995; 91: 28–36.
63. Correia AS, Matias G, Calado S, Lourenco A, Viana-Baptista M. Orolingual angiodema associated with alteplase treatment of acute stroke: a reappraisal. J Stroke Cerebrovasc Dis 2015; 24: 31–40.
64. Lin SY, Tang SC, Tsai LK, Yeh SJ, Hsiao YJ, Chen YW, Chen KH, Yip BS, Shen LJ, Wu FL, Jeng JS. Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use. Eur J Neurol 2014; 21: 1285–91.
65. Rudolf J, Grond M, Stenzel C, Neveling M, Heiss WD. Incidence of space-occupying brain edema following systemic thrombolysis of acute supratentorial ischemia. Cerebrovasc Dis 1998; 8: 166–71.
66. Unterberg A, Dautermann C, Baethmann A, Muller-Esterl W. The kallikrein–kinin system as mediator in vasogenic brain edema. Part 3: Inhibition of the kallikrein–kinin system in traumatic brain swelling. J Neurosurg 1986; 64: 269–76.
67. Bouma B, Maas C, Hazenberg BP, Lokhorst HM, Gebbink MF. Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost 2007; 5: 1139–42.
68. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarstrom P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208–18.
69. van der Linden PW, Hack CE, Eerenberg AJ, Struyvenberg A, van der Zwan JK. Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock. Blood 1993; 82: 1732–9.
70. van der Linden PW, Hack CE, Struyvenberg A, Roem D, Brouwer MC, de Boer JP, van der Zwan JK. Controlled insect-sting challenge in 55 patients: correlation between activation of plasminogen and the development of anaphylactic shock. Blood 1993; 82: 1740–8.
71. Clarke BJ, Cote HC, Cool DE, Clark-Lewis I, Saito H, Pixley RA, Colman RW, MacGillivray RT. Mapping of a putative surface-binding site of human coagulation factor XII. J Biol Chem 1989; 264: 11497–520.
72. Citarella F, te Velthuis H, Helmer-Citterich M, Hack CE. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII – an immunochemical and homology modeling approach. Thromb Haemost 2000; 84: 1057–65.
73. Mahdi F, Madar ZS, Figueroa CD, Schmaier AH. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99: 3585–96.
74. Maas C, Schiks B, Strangi RD, Hackeng TM, Bouma BN, Gebbink MF, Bouma B. Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs. Amyloid 2008; 15: 166–80.
75. Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 1987; 262: 10140–5.